Contact this trialFirst, we need to learn more about you.
Mitotic Inhibitor
Docetaxel +1 More for Non-Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Kansas City, Kansas
This trial is testing a new drug, pyrotinib, to see if it is more effective and has fewer side effects than the standard treatment, docetaxel, for patients with a specific type of lung cancer that has spread and who have not responded to other treatments.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.